AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34369697 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Baliao points combined with oral mifepristone (2 tablets daily)
Number of subjects: 58
Study 34369697 — intervention group
Group type: COMPARATOR
Intervention: Oral mifepristone (2 tablets daily)
Number of subjects: 58
Study 35302842 — intervention group
Group type: EXPERIMENTAL
Intervention: Case rate maps
Number of subjects: 0
Study 35302842 — intervention group
Group type: COMPARATOR
Intervention: County-level COVID case counts maps
Number of subjects: 0
Study 33208625 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO PET quantitative features
Number of subjects: 39
Study 33208625 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV-based features
Number of subjects: 39
Study 33208625 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVmax and total lesion CHO uptake
Number of subjects: 39
Study 33208625 — intervention group
Group type: EXPERIMENTAL
Intervention: Five alternative features (2 shape features and 3 SUV-based features)
Number of subjects: 39
Study 32957612 — intervention group
Group type: EXPERIMENTAL
Intervention: 336.4 mg of decaffeinated green tea catechins (GTC) after a single dose
Number of subjects: 0
Study 32957612 — intervention group
Group type: EXPERIMENTAL
Intervention: 336.4 mg of decaffeinated green tea catechins (GTC) after 12 weeks of daily intake
Number of subjects: 0
Study 36175971 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-IMPT with 5 mm geometric uncertainties
Number of subjects: 26
Study 36175971 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-IMPT with 3 mm geometric uncertainties
Number of subjects: 26
Study 36175971 — intervention group
Group type: COMPARATOR
Intervention: RO-IMPT
Number of subjects: 26
Study 33726718 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-hyaluronic acid mixture 0.1 mL (Test Group 1)
Number of subjects: 44
Study 33726718 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-hyaluronic acid mixture 0.2 mL (Test Group 2)
Number of subjects: 44
Study 33726718 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal (Control Group)
Number of subjects: 44
Study 32757521 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 849
Study 32757521 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 849
Study 35276764 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged black garlic (ABG) extract 250 mg (1.25 mg SAC)/tablet/day
Number of subjects: 67
Study 35276764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32709590 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie‐based self‐management exercise and education program
Number of subjects: 262
Study 32709590 — intervention group
Group type: COMPARATOR
Intervention: Single advice session over the phone
Number of subjects: 262
Study 35428594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided manual lymphatic drainage (MLD)
Number of subjects: 194
Study 35428594 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional manual lymphatic drainage (MLD)
Number of subjects: 194
Study 35428594 — intervention group
Group type: COMPARATOR
Intervention: Placebo manual lymphatic drainage (MLD)
Number of subjects: 194
Study 35428594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided MLD
Number of subjects: 194
Study 35428594 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional MLD
Number of subjects: 194
Study 35428594 — intervention group
Group type: COMPARATOR
Intervention: Placebo MLD
Number of subjects: 194
Study 34908913 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence medical intervention
Number of subjects: 447
Study 34908913 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 447
Study 32291223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM) plus exercises and advice
Number of subjects: 67
Study 32291223 — intervention group
Group type: COMPARATOR
Intervention: Exercises and advice
Number of subjects: 67
Study 35303118 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam
Number of subjects: 0
Study 35894292 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-Led Introduction to SolidS (BLISS)
Number of subjects: 101
Study 35894292 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 101
Study 35894292 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk consumption
Number of subjects: 101
Study 34162365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of Crosslinked Hyaluronic Acid Platform Hyaluronan (CHAP-HA)
Number of subjects: 140
Study 34162365 — intervention group
Group type: COMPARATOR
Intervention: Three injections of linear hyaluronan (linear-HA)
Number of subjects: 140
Study 34162365 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP-HA
Number of subjects: 140
Study 34162365 — intervention group
Group type: COMPARATOR
Intervention: linear-HA
Number of subjects: 140
Study 34162365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CHAP-HA and linear-HA
Number of subjects: 140
Study 32432566 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise selection algorithm for joint selection of fixed and random effects in mixed-effects models
Number of subjects: 0
Study 34657640 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arabinose (7.5 g) co-ingested with 50 g sucrose
Number of subjects: 12
Study 34657640 — intervention group
Group type: COMPARATOR
Intervention: Control (50 g sucrose without L-arabinose)
Number of subjects: 12
Study 32331937 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU
Number of subjects: 44
Study 32331937 — intervention group
Group type: COMPARATOR
Intervention: 1 ml sodium chloride 0.9 (placebo)
Number of subjects: 44
Study 33908312 — intervention group
Group type: EXPERIMENTAL
Intervention: MR stimulation (0.4 mg fludrocortisone + placebo)
Number of subjects: 116
Study 33908312 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA-R stimulation (placebo + 250 mg D-cycloserine)
Number of subjects: 116
Study 33908312 — intervention group
Group type: EXPERIMENTAL
Intervention: MR + NMDA-R stimulation (fludrocortisone + DCS)
Number of subjects: 116
Study 33908312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no pharmacological stimulation)
Number of subjects: 116
Study 32718702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) supplementation to the CPB circuit (40-ppm NO during CPB)
Number of subjects: 96
Study 32718702 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96
Study 32718702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) supplementation to the CPB circuit
Number of subjects: 96
Study 32150489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed-platinum
Number of subjects: 616
Study 32150489 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed-platinum
Number of subjects: 616
Study 35421222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Together and Reaching To Play
Number of subjects: 150
Study 35421222 — intervention group
Group type: COMPARATOR
Intervention: Movement, Orientation, Repetition, Exercise Physical Therapy
Number of subjects: 150
Study 33593332 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and nicotine replacement for 8 weeks, plus ongoing proactive outreach calls inviting reengagement in treatment.
Number of subjects: 38
Study 33593332 — intervention group
Group type: COMPARATOR
Intervention: Brief education and referral to the state quit line.
Number of subjects: 38
Study 33040018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with live born singletons
Number of subjects: 381
Study 32521007 — intervention group
Group type: EXPERIMENTAL
Intervention: Household approach (decolonization performed by all household members)
Number of subjects: 102
Study 32521007 — intervention group
Group type: COMPARATOR
Intervention: Personalized approach (decolonization performed only by household members who experienced SSTI)
Number of subjects: 102
Study 34915839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based secondary preventive care with consultations at 2 weeks, 3 months, 6 months, and 1 year after the index event and annually for up to 5 years.
Number of subjects: 1540
Study 34915839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based secondary preventive care
Number of subjects: 1540
Study 34915839 — intervention group
Group type: COMPARATOR
Intervention: Primary health care follow-up
Number of subjects: 1540
Study 35731756 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-robotic therapy
Number of subjects: 30
Study 35731756 — intervention group
Group type: COMPARATOR
Intervention: Robotic therapy
Number of subjects: 30
Study 35731756 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study 33243567 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 79
Study 33243567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 33243567 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 79
Study 33921227 — intervention group
Group type: EXPERIMENTAL
Intervention: HHCR (Hederacoside C from ivy leaf dry extracts and berberine from Coptidis rhizome dry extracts)
Number of subjects: 304
Study 33921227 — intervention group
Group type: EXPERIMENTAL
Intervention: HHCR
Number of subjects: 304
Study 33051032 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal training (HRT)
Number of subjects: 40
Study 33051032 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40
Study 35170228 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib granules (25 mg) under fed conditions
Number of subjects: 24
Study 35170228 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib capsules (50 mg [2 × 25 mg]) under fed conditions
Number of subjects: 24
Study 35170228 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib granules (25 mg) under fasted conditions
Number of subjects: 24
Study 35170228 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib capsules (50 mg [2 × 25 mg]) under fasted conditions
Number of subjects: 24
Study 35170228 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib administration with a low-fat meal
Number of subjects: 24
Study 34479574 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist assistance
Number of subjects: 8
Study 34479574 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosis assistance
Number of subjects: 8
Study 32853900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training for childbirth and parenting (eight 2-hour group sessions once a week and one 3-hour session of silent meditation)
Number of subjects: 0
Study 32853900 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone (Control)
Number of subjects: 0
Study 35220356 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0
Study 35220356 — intervention group
Group type: COMPARATOR
Intervention: Simulated Electroconvulsive Therapy (S-ECT)
Number of subjects: 0
Study 32051080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine adjuvant therapy
Number of subjects: 100
Study 32051080 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study 36278971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower target for oxygen saturation (90%; goal range, 88 to 92%)
Number of subjects: 2541
Study 36278971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate target for oxygen saturation (94%; goal range, 92 to 96%)
Number of subjects: 2541
Study 36278971 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher target for oxygen saturation (98%; goal range, 96 to 100%)
Number of subjects: 2541
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes (diet, physical activity, stress level, alcohol and nicotine consumption) after cancer diagnosis
Number of subjects: 141
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fruit and vegetable consumption
Number of subjects: 141
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced meat consumption
Number of subjects: 141
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in physical activity
Number of subjects: 141
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in perceived stress level
Number of subjects: 141
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation or reduction
Number of subjects: 141
Study 34182983 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in alcohol consumption
Number of subjects: 141
Study 36036836 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive Er:YAG laser with SMOOTH mode (NightLase)
Number of subjects: 0
Study 34160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered endovascular reconstruction of aortic bifurcation (CERAB)
Number of subjects: 116
Study 35168640 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health advisor (CHA) intervention with a 6-week CRC educational program including an initial face-to-face meeting followed by 5 weeks of calls and texts, along with a brochure.
Number of subjects: 0
Study 35168640 — intervention group
Group type: COMPARATOR
Intervention: Brochure only (control group).
Number of subjects: 0
Study 32540793 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 450
Study 32540793 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 450
Study 32540793 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 450
Study 35728680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 29
Study 32160968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-moderate supervised exercise program (IG)
Number of subjects: 92
Study 32160968 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 92
Study 34894627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised in-school combined resistance and aerobic training program (2 × 60-minute sessions per week)
Number of subjects: 99
Study 34894627 — intervention group
Group type: COMPARATOR
Intervention: Curriculum physical education (2 × 60-minute sessions per week)
Number of subjects: 99
Study 34894627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised in-school combined resistance and aerobic training program (2 × 60-minute sessions per week) in lower birthweight subgroup
Number of subjects: 99
Study 34894627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised in-school combined resistance and aerobic training program (2 × 60-minute sessions per week) in normal birthweight subgroup
Number of subjects: 99
Study 33221705 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed PlGF testing and management guidance
Number of subjects: 1006
Study 33221705 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1006
Study 32912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to a telephone-based risk-assessment for a Lung Health Check
Number of subjects: 62980
Study 32912947 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62980
Study 34379607 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 1.2g of protein plus high-protein supplement (36g whey protein)
Number of subjects: 0
Study 34379607 — intervention group
Group type: COMPARATOR
Intervention: Starch as a placebo
Number of subjects: 0
Study 34931494 — intervention group
Group type: EXPERIMENTAL
Intervention: BR‐TD‐1001
Number of subjects: 218
Study 34931494 — intervention group
Group type: COMPARATOR
Intervention: Td (Td‐pur, GlaxoSmithKline)
Number of subjects: 218
Study 35963046 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-enhanced interdisciplinary home visits (IN-HOME-PD)
Number of subjects: 65
Study 35963046 — intervention group
Group type: COMPARATOR
Intervention: Usual care (POP controls)
Number of subjects: 65
Study 35963046 — intervention group
Group type: COMPARATOR
Intervention: Comparison between IN-HOME-PD and POP controls
Number of subjects: 65
Study 33483108 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS intervention (community-based and peer-delivered sexual health promotion motivational interviewing-based intervention)
Number of subjects: 0
Study 33483108 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS intervention
Number of subjects: 0
Study 33926540 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief exposure to online text and image‐based messages addressing necessity beliefs and concerns about COVID‐19 vaccination.
Number of subjects: 1094
Study 33926540 — intervention group
Group type: COMPARATOR
Intervention: Brief exposure to online text and image‐based messages containing general information about COVID‐19 and COVID‐19 vaccination.
Number of subjects: 1094
Study 32031088 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 20
Study 32031088 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 20
Study 36256600 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 27
Study 36256600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33537860 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning trained on time-frequency acoustic spectra
Number of subjects: 13
Study 33537860 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 13
Study 32450063 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable rigid dressing (RRD)
Number of subjects: 25
Study 32450063 — intervention group
Group type: COMPARATOR
Intervention: Elastic bandage (EB)
Number of subjects: 25
Study 35353887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (40-min, 77.5 Hz, 15 mA, one forehead and two mastoid sessions)
Number of subjects: 100
Study 35353887 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100
Study 35353887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 100
Study 35353887 — intervention group
Group type: COMPARATOR
Intervention: Active stimulation and Sham stimulation
Number of subjects: 100
Study 34163159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin mucoadhesive nanosuspension nasal spray twice daily plus Egyptian protocol for mild COVID-19
Number of subjects: 114
Study 34163159 — intervention group
Group type: COMPARATOR
Intervention: Egyptian protocol for mild COVID-19 only
Number of subjects: 114
Study 34163159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin mucoadhesive nanosuspension nasal spray
Number of subjects: 114
Study 32791499 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 100
Study 32791499 — intervention group
Group type: COMPARATOR
Intervention: Verbal education
Number of subjects: 100
Study 35144924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab intensified regimen (IR, 900 mg ×3, 300 mg thereafter)
Number of subjects: 147
Study 35144924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab intensified regimen (IR)
Number of subjects: 147
Study 35144924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anifrolumab (BR and IR)
Number of subjects: 147
Study 35144924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 35144924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab basic regimen (BR, 300 mg)
Number of subjects: 147
Study 33944577 — intervention group
Group type: EXPERIMENTAL
Intervention: Conidial suspension (10^5 ml^-1) from a 15-day-old culture of F. ipomoeae
Number of subjects: 22
Study 33944577 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 22
Study 32705833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion applied 2 hours after chemotherapy for 20 min each time, once daily for 3 days
Number of subjects: 60
Study 32705833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion
Number of subjects: 60
Study 32705833 — intervention group
Group type: COMPARATOR
Intervention: Control group received intravenous injection of Tropisetron (5 mg) 1 h before chemotherapy
Number of subjects: 60
Study 36721509 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg daily for five days
Number of subjects: 151
Study 36721509 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 gram daily and azithromycin 500 mg daily for 5-7 days
Number of subjects: 151
Study 35687107 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 9583
Study 35687107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9583
Study 34265173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide monotherapy (200-600 mg/day)
Number of subjects: 106
Study 36444879 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BBAT) 3 days a week for 6 weeks in addition to a home-based exercise programme
Number of subjects: 40
Study 33993600 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Maternity Waiting Home (MWH) model
Number of subjects: 40
Study 32353635 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision‐Rule Based Treatment (DR)
Number of subjects: 30
Study 32353635 — intervention group
Group type: COMPARATOR
Intervention: Sequential Treatment (SEQ)
Number of subjects: 30
Study 36323718 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 42
Study 36323718 — intervention group
Group type: COMPARATOR
Intervention: Standing group
Number of subjects: 42
Study 36323718 — intervention group
Group type: EXPERIMENTAL
Intervention: Green spaces
Number of subjects: 42
Study 36323718 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor urban space
Number of subjects: 42
Study 33828171 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Compliance Index (TCI) measured using anthropometrically-matched, suddenly-applied pulling perturbations to the trunk segment across three planes of motion (antero-posterior, medio-lateral, and rotational).
Number of subjects: 49
Study 33828171 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operator Characteristic (ROC) analysis of TCI.
Number of subjects: 49